Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company focusing on the development of products using its drug delivery platform technology. While facing challenges such as the recent CEO change and adjusted EPS estimates, the potential for approval and commercialization of CTx-1301 in mid-2026 may serve as a strong catalyst for the stock, with a current valuation that appears attractive and a BUY rating being maintained. Risks to consider include potential difficulties in gaining regulatory approval and market competition.

Bears say

Cingulate is primarily focused on developing therapeutics for ADHD and anxiety, which have a high prevalence and represent a large market opportunity. However, with numerous established competitors in the ADHD market and no current products on the market, Cingulate may have difficulty gaining a significant share of the market and generating substantial revenue. Additionally, the company's lack of diversification and dependence on the success of its two lead medications could make it vulnerable to market fluctuations and potential setbacks in clinical trials.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.